<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> (CKD) is a risk factor for <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo> (LVH) and <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the effect of CKD on left ventricular (LV) remodelling among patients with mild <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: REVERSE was a randomized, controlled trial evaluating cardiac resynchronization therapy (CRT) in patients with New York Heart Association (NYHA) class I/II <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>CKD was defined as an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m(2) </plain></SENT>
<SENT sid="4" pm="."><plain>We compared changes in LV function and size over the course of 12 months by CKD status using linear mixed models adjusted for demographics, co-morbidities, medications, <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> aetiology, and CRT status </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, we evaluated the effect of CKD on cardiac remodelling among patients randomized to CRT on or off </plain></SENT>
<SENT sid="6" pm="."><plain>CKD was associated with worsening LV function and dilation compared with the non-CKD group {adjusted, 12-month Î² coefficients for the CKD group compared with the non-CKD referent group: LV ejection fraction (%) [-1.80, 95% confidence interval (CI) -3.36 to -0.24], LV end-systolic volume (mL) (14.16, 95% CI 3.96-24.36), LV end-diastolic volume (mL) (14.88, 95% CI 2.88-26.76), LV end-systolic diameter (cm) (0.36, 95% CI 0.12-0.48), LV end-diastolic diameter (cm) (0.24, 95% CI 0.012-0.36), <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> (%) (3.12, 95% CI 0.48-5.76), and LV shape (0.036, 95% CI 0.012-0.060)} </plain></SENT>
<SENT sid="7" pm="."><plain>In participants assigned to CRT, those without CKD had significantly greater improvements in LV structural parameters compared with the CKD group </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In comparison with participants with <z:mpath ids='MPATH_458'>normal</z:mpath> kidney function, CKD is an independent risk factor for ventricular dysfunction and dilation </plain></SENT>
<SENT sid="9" pm="."><plain>CRT improves LV function and structure to a lesser extent in patients with CKD than in those with <z:mpath ids='MPATH_458'>normal</z:mpath> kidney function </plain></SENT>
</text></document>